X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
PFIZER LIMITED Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

PFIZER LIMITED   (PFIZ)


Here is the latest financial fact sheet of Pfizer. For more details, see the Pfizer quarterly results and Pfizer share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
PFIZER - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 1,751.8       No. of shares m 45.75
    Mkt Cap Rs m 80,145       % ch % -0.9
    Vol '000 39.5       % ch week % 1.7
    P/E X 23.9       % ch 1-mth % -1.0
    P/CF X 23.1       % ch 12-mth % 2.3
    EPS (TTM) Rs 73.4       52 week H/L Rs 2,055.0/1,651.1
(As on Mar 23, 2017 (Close)) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Mar-12
12
Mar-13
12
Mar-14
12
Mar-15
12
Mar-16
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs1,6361,4101,7792,3252,724 
Low Rs1,0729999851,1751,611 
Sales per share (Unadj.) Rs366.4351.5372.6405.1440.9 
Earnings per share (Unadj.) Rs61.9168.674.015.348.7 
Diluted earnings per shareRs40.4110.048.315.348.7 
Cash flow per share (Unadj.) Rs65.1171.376.743.975.8 
Dividends per share (Unadj.) Rs12.5032.50360.0012.5015.00 
Adj. dividends per shareRs8.1521.20234.8112.5015.00 
Dividend yield (eoy) %0.92.726.00.70.7 
Book value per share (Unadj.) Rs437.2567.8220.6431.3462.9 
Adj. book value per shareRs285.2370.4143.9431.3462.9 
Shares outstanding (eoy) m29.8429.8429.8445.7545.75 
Bonus/Rights/Conversions  ---A- 
Price / Sales ratio x3.73.43.74.34.9 
Avg P/E ratio x21.97.118.7114.744.5 
P/CF ratio (eoy) x20.87.018.039.928.6 
Price / Book Value ratio x3.12.16.34.14.7 
Dividend payout %20.219.3486.481.930.8 
Avg Mkt Cap Rs m40,40335,93641,23980,06399,163 
No. of employees `0003.22.82.4NA2.9 
Total wages/salary Rs m1,9282,1111,9182,3642,758 
Avg. sales/employee Rs Th3,469.73,752.64,600.0NM6,981.7 
Avg. wages/employee Rs Th611.9755.3793.4NM954.5 
Avg. net profit/employee Rs Th585.91,800.4913.8NM771.1 
  INCOME DATA
Net Sales Rs m10,93310,48811,11818,53320,170 
Other income Rs m9271,0521,094674857 
Total revenues Rs m11,86011,54112,21219,20721,028 
Gross profit Rs m1,9531,8272,3853,8304,310 
Depreciation Rs m9680801,3111,239 
Interest Rs m62485 
Profit before tax Rs m2,7792,7973,3963,1853,923 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m-44,1410-1,11099 
Tax Rs m9291,9061,1871,3771,794 
Profit after tax Rs m1,8465,0322,2096982,228 
Gross profit margin %17.917.421.520.721.4 
Effective tax rate %33.468.135.043.245.7 
Net profit margin %16.948.019.93.811.0 
  BALANCE SHEET DATA
Current assets Rs m13,30818,0446,86012,52016,299 
Current liabilities Rs m2,5103,5093,0346,0857,594 
Net working cap to sales %98.8138.634.434.743.2 
Current ratio x5.35.12.32.12.1 
Inventory Days Days6157507665 
Debtors Days Days4749573226 
Net fixed assets Rs m3192592329,5698,622 
Share capital Rs m298298298458458 
"Free" reserves Rs m12,74916,6466,28619,27320,722 
Net worth Rs m13,04716,9446,58419,73021,180 
Long term debt Rs m0002525 
Total assets Rs m15,81620,5959,76726,13729,137 
Interest coverage x472.01,166.2944.3414.6755.5 
Debt to equity ratio x00000 
Sales to assets ratio x0.70.51.10.70.7 
Return on assets %11.724.422.72.77.7 
Return on equity %14.129.733.53.510.5 
Return on capital %21.341.051.610.519.0 
Exports to sales %0.20.100.10.1 
Imports to sales %9.48.99.423.117.5 
Exports (fob) Rs m17125912 
Imports (cif) Rs m1,0309321,0504,2743,526 
Fx inflow Rs m2211558311752 
Fx outflow Rs m1,1601,2659,4314,383140 
Net fx Rs m-939-1,110-9,348-4,266-88 
  CASH FLOW
From Operations Rs m 245 -160 1,325 1,135 3,436 
From Investments Rs m 2,775 6,259 1,027 -888 -6,991 
From Financial Activity Rs m -141 -432 -13,602 -14 -619 
Net Cashflow Rs m 2,879 5,667 -11,251 233 -4,174 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for pfizer limited

 Share Holding
Indian Promoters : 0.0%
Foreign collaborators : 63.9%
Indian inst/Mut Fund : 7.5%
FIIs : 4.9%
ADR/GDR : 0.0%
Free float : 23.7%
Shareholders : 85,207
Pledged promoter(s) holding : 0.0%
 Company Information
Top
    REGD OFF: Pfizer Centre, Patel Estate, S. V. Road, Jogeshwari (W), Mumbai - 400 102
    E-MAIL: prajeet.nair@pfizer.com     WEB: www.pfizerindia.com
    TELEPHONE: (022) 6693 2000     FAX: (022) 2678 4569
    SECTOR: PHARMACEUTICALS     GROUP: M N C
    TR AGENT: Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
    AUDITOR: B S R & Co. LLP
CHM: R. A. Shah COMP SEC: Prajeet Nair YEAR OF INC: 1950 BSE CODE: 500680 FV (Rs): 10 DIV YIELD (%): 0.9

More pharmaceuticals Company Fact Sheets:   WOCKHARDT LTD.TORRENT PHARMAORCHID PHARMA LTDALEMBIC PHARMASUVEN LIFE


Today's Market

Sensex Closes Firm; NTPC Surges 2.3%(Closing)

Indian share markets continued to trade higher owing to firm global cues with energy stocks leading the gains, while financial stocks and auto stocks bounced back.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Bluechips Have 60% Chance Of Losing Money At Current Levels. But a Small Group Won't...(The 5 Minute Wrapup)

Mar 17, 2017

The trend that makes a select group of bluechip stocks inherently safer even at peak index valuations.

As Digital Transactions Fall, Indians Are Going Back to Cash(Vivek Kaul's Diary)

Mar 16, 2017

Digital transactions have fallen since December 2016 both in value and volume terms.

Stock Markets and Gold Rally, Dollar Tumbles(Chart Of The Day)

Mar 16, 2017

Markets are moving up even after the fed interest rate hike.

Why You Should Try SCOREFASTTM Right Now(Daily Profit Hunter)

Mar 10, 2017

Asad Dossani discusses why SCOREFASTM will be a successful trading strategy

4 Things To Watch Out For After Modi's Landslide Win In UP Polls(Outside View)

Mar 15, 2017

PersonalFN explains why you need to wary while investing in equities despite Modi's UP win.

More

TRACK PFIZER

MORE ON PFIZER

PFIZER 8-QTR ANALYSIS

Detailed Quarterly Results With Charts

COMPARE PFIZER WITH

MARKET STATS